IAS News and Literature Updates:
June 2017
From the President's Desk:
Yuji Matsuzawa

As a follow up to my February message to you concerning the important contribution of excess visceral fat to the development of atherosclerosis directly or through cardiovascular risks, the IAS established the IAS Working Group on Visceral Obesity and Cardiovascular Disease which held its inaugural meeting of the Working Group in Prague, Czech Republic during the EAS Congress last April. The intent was to better understand the importance of assessing/targeting abdominal obesity, particularly when associated with excess visceral/ectopic fat, as an important driver of the cardiometabolic risk that has been associated in the past with overweight/obesity per se.


IAS Visiting Fellowship Opportunities
Application Deadline: January 31, 2018
3 - Month Visiting Fellowship Award $5,000
• 6 - Month Visiting Fellowship Award $8,000
For the Flyer Click Here
For more information Click Here

Educational intervention to improve effectiveness in treatment and control of patients with high cardiovascular risk in low-resource settings in Argentina: study protocol of a cluster randomised controlled trial    
Hypercholesterolaemia, a condition that accounts for a significant disease burden in the developed and developing world, is estimated to cause 2.6 million deaths annually (4.5% of all deaths) and one-third of the cases of ischaemic heart disease.1 Globally, mean total cholesterollevels changed little between 1980 and 2008, falling by <0.1 mmol/L per decade for men and women. In 2008, the global prevalence of elevated total cholesterol among adults was 39% (37% for males and 40% for females).

> Complete Article <
Also included in this Newsletter:

Toronto, Canada
June 9 - 12, 2018

XVIII International Symposium on Atherosclerosis

In the News: 

Observational Studies and Unknown Confounding Factors

By: Hirotsugu Ueshima

Observational studies are important and useful analytical designs in epidemiology for elucidating possible risk factor associations with important disease outcomes. However, the most difficult issue is how to control for possible confounding factors. Typically, confounding factors are often defined as those having an influence on a perceived relationship between a risk factor and disease. Careful analyses that attempt to adjust or account for this confounding include several approaches. The simplest approach is through stratification, as with a separate analysis for men and women. Model-based approaches include the adjustment for a confounder by its addition as an independent variable in a model that includes the primary risk factor of interest as a predictor of the disease outcome.

View Complete Commentary <

Apolipoprotein M and Sphingosine 1-Phosphate Are New Key Molecules for CETP Involvement in Atherosclerosis
By: Makoto Kurano and Yutaka Yatomi

Cholesteryl ester transfer protein (CETP) affects the dynamism of HDL; CETP transfers cholesteryl ester from HDL to apoB-containing lipoproteins, while it transfers triglycerides from apoB-containing lipoproteins to HDL. Contrary to this established role of CETP in the reverse transport system of cholesterol, the significance of CETP in the pathogenesis of atherosclerosis remains to be elucidated; it is still controversial whether individuals lacking CETP are resistant to atherosclerotic diseases and CETP inhibitors, which were expected to be novel medicines for the treatment of subjects with low HDL cholesterol levels who are prone to suffer from atherosclerotic diseases, failed to protect against atherosclerotic diseases successfully.

> View Complete Commentary <


July 13-14, 2017

Chilean Working Group on Atherosclerosis 2nd Course: Update on Cardiovascular Risk Factors: From Theory to Clinical Practice
Santiago, Chile

Email: rodrigoalonsok@gmail.com  

September 14-15, 2017

Intersociety Session SAL-IAS-SAC: Synergy to Deal with the Challenges XIV Annual Meeting of the Argentine Society of Lipids: Chemistry, biology, genetic: two decades
Buenos Aires, Argentina

View Meeting Website

November 23-25, 2017

XXXVIII Congreso Chileno de Medicina Interna 2017“Controversias en Medicina Interna, una oportunidad de aprendizaje”
Vina del Mar, Chile

Email: rodrigoalonsok@gmail.com

December 1-2, 2017

7th Symposium of the Working Groups of the Hellenic Atherosclerosis Society
Athens, Greece

View Meeting Website 

February 27 - March 1, 2018

Philippine Lipid and Atherosclerosis Society 
11th APSAVD Congress Annual Scientific Meeting
Iloilo City, Philippines

View Meeting Website 

For a complete listing of all Member Society meetings and educational activities

Please Click Here


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2017 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile